- Home
- ECOR vs RANI Comparison
ECOR vs RANI Comparison
Compare ECOR & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- RANI
- Stock Information
- Founded
- ECOR 2005
- RANI 2012
- Country
- ECOR United States
- RANI United States
- Employees
- ECOR N/A
- RANI N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RANI Medicinal Chemicals and Botanical Products
- Sector
- ECOR Health Care
- RANI Health Care
- Exchange
- ECOR Nasdaq
- RANI Nasdaq
- Market Cap
- ECOR 87.1M
- RANI 73.8M
- IPO Year
- ECOR 2018
- RANI 2021
- Fundamental
- Price
- ECOR $10.94
- RANI $2.27
- Analyst Decision
- ECOR Strong Buy
- RANI Strong Buy
- Analyst Count
- ECOR 1
- RANI 5
- Target Price
- ECOR $15.00
- RANI $11.80
- AVG Volume (30 Days)
- ECOR 157.1K
- RANI 762.4K
- Earning Date
- ECOR 11-13-2024
- RANI 11-14-2024
- Dividend Yield
- ECOR N/A
- RANI N/A
- EPS Growth
- ECOR N/A
- RANI N/A
- EPS
- ECOR N/A
- RANI N/A
- Revenue
- ECOR $23,327,000.00
- RANI N/A
- Revenue This Year
- ECOR $62.51
- RANI N/A
- Revenue Next Year
- ECOR $31.32
- RANI N/A
- P/E Ratio
- ECOR N/A
- RANI N/A
- Revenue Growth
- ECOR 74.10
- RANI N/A
- 52 Week Low
- ECOR $5.02
- RANI $1.90
- 52 Week High
- ECOR $14.20
- RANI $8.75
- Technical
- Relative Strength Index (RSI)
- ECOR 49.51
- RANI 44.83
- Support Level
- ECOR $10.40
- RANI $2.32
- Resistance Level
- ECOR $14.20
- RANI $2.67
- Average True Range (ATR)
- ECOR 1.25
- RANI 0.16
- MACD
- ECOR -0.14
- RANI -0.01
- Stochastic Oscillator
- ECOR 14.21
- RANI 11.11
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.